ArticleFrontiers in immunology2026
Administration with carnosic acid alleviates the development of osteoarthritis by attenuating macrophage polarization-mediated inflammation and cartilage oxidative damage and degradation via regulating Nrf2/NF-kB axis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Osteoarthritis (OA) is a common inflammatory degenerative joint disease characterized by deterioration of articular cartilage. Macrophages exert the important roles in cartilage damage and synovial inflammation in OA. Carnosic acid (CA) possesses critical function in multiple inflammatory diseases. Methods: Macrophages were treated with carnosic acid. Chondrocytes were incubated with conditioned medium (CM) from macrophages. Then, the effects on macrophage polarization were analyzed. The effects on chondrocyte oxidative injury, inflammation and extracellular matrix (ECM) metabolism imbalance were explored. Carnosic acid was administrated to Anterior cruciate ligament transection (ACLT)-constructed OA mice model. Then, the efficacy of carnosic acid in the progression of OA was further explored. Results: Carnosic acid inhibited LPS-induced macrophage M1 polarization and enhanced IL-4-evoked macrophage M2-like polarization. Furthermore, conditioned medium (CM) from M1 macrophages induced chondrocyte oxidative injury, which were abrogated by carnosic acid. Concomitantly, carnosic acid restrained M1 macrophage CM-increased inflammatory mediator and inflammatory cytokine IL-6 and TNF-α contents. Moreover, carnosic acid also antagonized M1 macrophage CM-evoked extracellular matrix (ECM) degradation. Mechanistically, carnosic acid enhanced Nrf2 expression and suppressed subsequent activation of the NF-κB signaling. Intriguingly, Nrf2 inhibition restrained activation of the NF-κB signaling and reversed carnosic acid-mediated suppression on macrophage M1-like polarization. Furthermore, carnosic acid attenuated M1 macrophage-induced oxidative injury, inflammatory response and ECM metabolism disturbance of chondrocytes. Discussion: Carnosic acid may alleviate the progression of OA by attenuating macrophage polarization-mediated inflammatory response and cartilage oxidative damage via regulating Nrf2/NF-kB axis, supporting it as a promising and potential therapeutic agent for patients with OA in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.